Member Info for dallo

Oldernowiser

I suspect the market will not get too excited as the odds of Karuna shareholders not approving the BMS takeover were very small

Hopefully some positive reaction though with the uncertainty now gone.

I would be delighted with a 10% uplift in the morning.

Exactly as I predicted.

Let's see what the markets think in the morning

ATB

Steven

Again another silly piece of conjecture on your part

Here are the facts Lanstead held 15.8% as of December 2023 and it must issue a holdings RNS if its holding goes below 15% under Stock Exchange rules.

So far Lanstead hasn't done so which makes your comment about Lanstead dumping shares extremely circumstantial and frankly utterly useless to the debate.

Wildbunch

Nobody should fear divergent views on shares and everyone has their opinions but on a share forum when you see scaremongering about liquidation or another death spiral placing from posters with no investment in Immupharma, you have to query their motives.

What satisfaction do these people get out of opining on the demise of Immupharma without looking at the positive progress made in the past 2 years since we got the Alora Group on board , got rid of Zimmerman, Dimitriou et al and worked assiduously on a formula for Lupuzor trial with the US FDA and expanded Immupharma's suite of drugs to include CIDP and the Anti Infectives plus finally seeing great potential in Incanthera's Sol anti cancer suncream now being distributed through the largest cosmetic chain , AS Watson part of the mega CK Hutchison Group.

Also according to the naysayers 2 weeks ago, Immupharma could not get funding but now have possibly 3 sources should it need it....Warrants, Commercial deals or Incanthera financial asset.

At a market cap of c£5m surely even the doomsday scenarios look absurd.

At least Lambo the arch bear has had the decency to withdraw from the discussions.

ATB

Flash

If you are concerned about Immupharma and fear losing your money, in your view, in a bad stock then my simple advice is...DONT BUY ANY SHARES IN THE COMPANY.

ATB

Pokerchips

Doesn't worry me at all because I have added to my holding in past 2 weeks at below 1.2p so won't be diluted from previous levels.

In the context of the liquidation/ heavily discounted placing fears of 2 weeks ago, I will accept the exercise of the 2p warrants given that the SP would have to be much higher than 2p for a sustained period before warrant holders can be persuaded to exercise.

ATB

Flash

You are an absolute genius.

If the 100 m warrants are exercised at 2p, then that's £2m cash into the company.

And then you say Immupharma needs a placing.

Clown

And another trade at 1.78p

Up 20%

Obviously Moneymule and others here are not so stupid as to invest in this company but out of the goodness of their kind hearts, take time to warn investors in Immupharma of their impending doom .

As for Oscar offering hope to the guileless fools like me, maybe hope keeps everyone going in all aspects of life.

Another buy trade at 1.74p...oh what fool has done such a act of reckless folly.

Hopefully we will get positive Puretech share price action today on the expected Karuna shareholders approval of the BMS offer at the EGM.

Oscar

Well done

Volumes increasing ..3m buys today and looks like Lanstead not reducing below notifiable 15% .

As I said to Lisa any positive news on commercial deals on Lupuzor and CIDP and the anti infective programme would give the SP a massive boost.

The $billion Alora Group still committed to the $25m Phase 3 Lupuzor trial and Simbec-Orion appointed to run both the Lupuzor Phase 3 and CIDP Phase 2/3 trial with guidance submissions in with the FDA on the latter.

I cannot think of an AIM Pharma minnow with the potential upside than Immupharma and don't forget the Anti Infective drugs plus the potential blockbuster in Incanthera.

All for the knockdown price of a few million quid.

Cheers

.

JSB

You are quite correct about the EGM as the Karuna Directors would have sounded out most if not all of the major Institutional Investors before calling the EGM and agreeing provisional terms with BMS.

The litigation is standard procedure in most US acquisitions with the motive being to sweeten the deal. Lawyers get a cut of any uplift in the acquisition price through litigation pressure ( blackmail) and maybe there will be a bone thrown at the EGM but I doubt it.

If there were other serious bidders around they would have moved by now.

The issue of the royalties to be paid to Puretech/ Royalty Pharma is a big issue for Bristol Meyers and that could lead to further corporate action.

ATB

Golf nut

In the unlikely event that Karuna shareholders vote against the BMS takeover , it only means that the price of the bid is too low and then would immediately open up a bidding war as other major Pharmas make their move.

Either way still great for Puretech imho.

Cauldstream

Cheers

I think a few doomsday posters here had an influence on persuading nervous investors to exit with liquidation/ massive dilution placing rumours which management became aware of and acted accordingly after representations from myself and other investors.

Mysticmike

A thoroughly scurrilous and inane comment .

So Tim doesn't release a RNS for 3 months so he risks his whole reputation to allow a few mates to make a couple of grand as the volumes on the way down from 1.5p to .9p were miniscule.

We can all buy now at 1.3 /1.4p so what a multi bagger for Tim's mates.

Idiot

Synoogold

I have been here for nearly 9 years now and remember Eva et al.

I have been a critic of McCarthy over the years but I thought he was excellent and measured ( by his standards) in the Proactive interview today.

I have spent the last week urging Immupharma management to issue an update to the market and I think they have delivered a well thought out and reassuring message to Investors and the market.

Tim's belief that Incanthera could be a €100 m company may be slightly OTT but even €50m could see this Immupharma investment valued in excess of the current market cap of Immupharma.

He has nailed his reputation and that of whole management on saying that there will be no dilutive

fund raise and with potential commercial licensing deals allied to the supportive Incanthera financial asset, I believe him.

Immupharma at a market cap of c5m looks like a potentially rewarding investment imho and will buy more tomorrow.

DYOR

ATB to real investors.

****nal

i cannot find relevant puretech mention in tipranks.

anything of interest

Mr Brain

Good summary. I couldn't put in better myself.

I am buying again today and order in

Atb

1.55p and rising

In auction with MMs trying to match huge buy trades

with no sellers.

Looks good for a big rise once trades are unlocked

ATB